Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy La Jolla Pharmaceutical Company stock

Own La Jolla Pharmaceutical Company stock in just a few minutes.

La Jolla Pharmaceutical Company is a biotechnology business based in the US. La Jolla Pharmaceutical Company shares (LJPC) are listed on the NASDAQ and all prices are listed in US Dollars. La Jolla Pharmaceutical Company employs 59 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in La Jolla Pharmaceutical Company

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LJPC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

La Jolla Pharmaceutical Company share price

Use our graph to track the performance of LJPC stocks over time.

La Jolla Pharmaceutical Company shares at a glance

Information last updated 2021-04-30.
52-week range$3.36 - $8.10
50-day moving average $4.48
200-day moving average $4.80
Wall St. target price$9.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.92

Buy La Jolla Pharmaceutical Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy La Jolla Pharmaceutical Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

La Jolla Pharmaceutical Company financials

Revenue TTM $33.4 million
Gross profit TTM $28.1 million
Return on assets TTM -15.81%
Return on equity TTM 0%
Profit margin -117.96%
Book value $-0.61
Market capitalisation $116.3 million

TTM: trailing 12 months

Shorting La Jolla Pharmaceutical Company shares

There are currently 3.1 million La Jolla Pharmaceutical Company shares held short by investors – that's known as La Jolla Pharmaceutical Company's "short interest". This figure is 2% up from 3.0 million last month.

There are a few different ways that this level of interest in shorting La Jolla Pharmaceutical Company shares can be evaluated.

La Jolla Pharmaceutical Company's "short interest ratio" (SIR)

La Jolla Pharmaceutical Company's "short interest ratio" (SIR) is the quantity of La Jolla Pharmaceutical Company shares currently shorted divided by the average quantity of La Jolla Pharmaceutical Company shares traded daily (recently around 225879.45306726). La Jolla Pharmaceutical Company's SIR currently stands at 13.53. In other words for every 100,000 La Jolla Pharmaceutical Company shares traded daily on the market, roughly 13530 shares are currently held short.

However La Jolla Pharmaceutical Company's short interest can also be evaluated against the total number of La Jolla Pharmaceutical Company shares, or, against the total number of tradable La Jolla Pharmaceutical Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case La Jolla Pharmaceutical Company's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 La Jolla Pharmaceutical Company shares in existence, roughly 110 shares are currently held short) or 0.163% of the tradable shares (for every 100,000 tradable La Jolla Pharmaceutical Company shares, roughly 163 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against La Jolla Pharmaceutical Company.

Find out more about how you can short La Jolla Pharmaceutical Company stock.

La Jolla Pharmaceutical Company share dividends

We're not expecting La Jolla Pharmaceutical Company to pay a dividend over the next 12 months.

Have La Jolla Pharmaceutical Company's shares ever split?

La Jolla Pharmaceutical Company's shares were split on a 1:50 basis on 13 January 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your La Jolla Pharmaceutical Company shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for La Jolla Pharmaceutical Company shares which in turn could have impacted La Jolla Pharmaceutical Company's share price.

La Jolla Pharmaceutical Company share price volatility

Over the last 12 months, La Jolla Pharmaceutical Company's shares have ranged in value from as little as $3.36 up to $8.1. A popular way to gauge a stock's volatility is its "beta".

LJPC.US volatility(beta: 2.39)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while La Jolla Pharmaceutical Company's is 2.3944. This would suggest that La Jolla Pharmaceutical Company's shares are significantly more volatile than the average for this exchange and represent a higher risk.

La Jolla Pharmaceutical Company overview

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company was incorporated in 1989 and is headquartered in San Diego, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site